Chuck Akre’s SOPHiA GENETICS SOPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.5M Hold
3,719,140
0.42% 16
2026
Q1
$18.4M Hold
3,719,140
0.3% 17
2025
Q4
$17.4M Hold
3,719,140
0.19% 15
2025
Q3
$17.7M Hold
3,719,140
0.18% 16
2025
Q2
$11.5M Buy
3,719,140
+1,481,636
+66% +$4.42M 0.11% 16
2025
Q1
$7.43M Hold
2,237,504
0.07% 16
2024
Q4
$6.87M Hold
2,237,504
0.06% 17
2024
Q3
$8.17M Buy
2,237,504
+317,072
+17% +$1.29M 0.07% 16
2024
Q2
$8.8M Buy
1,920,432
+1,632,733
+568% +$7.96M 0.08% 17
2024
Q1
$1.42M Buy
+287,699
New +$1.39M 0.01% 20

Other funds holding SOPH

Chuck Akre's SOPH Position: Q2 2026 in Review

Chuck Akre held its SOPHiA GENETICS (SOPH) position steady in Q2 2026 at 3,719,140 shares worth $21.5M. The position accounts for 0.42% of the portfolio, ranked #16.

Chuck Akre first reported a position in SOPH in Q1 2024 and has held it in 10 quarters since. 72 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Chuck Akre held 3,719,140 shares of SOPHiA GENETICS worth $21.5M as of Q2 2026.
  • Chuck Akre left its SOPHiA GENETICS share count unchanged in Q2 2026.
  • SOPHiA GENETICS made up 0.42% of Chuck Akre's portfolio in Q2 2026, its #16 holding.
  • Chuck Akre first reported a position in SOPHiA GENETICS in Q1 2024 and has held it in 10 quarters since.
  • 72 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on AKRE Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.